Tailored hormone dosing may spare preemies from blood transfusions

NCT ID NCT02075970

Completed Disease control Sponsor: University of Iowa Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether personalized dosing of epoetin alfa—a lab-made hormone that boosts red blood cell production—can reduce or eliminate the need for blood transfusions in very low birth weight premature infants with neonatal anemia. Researchers will study how the drug behaves in the body and identify which infants are most likely to respond well. The goal is to develop a tailored treatment strategy that could transform care for these vulnerable newborns.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: epoetin alfa (Procrit), a lab-made hormone that stimulates red blood cell production
What this could lead to: If successful, this approach could reduce or eliminate the need for blood transfusions in many premature infants with anemia.
What could go wrong: This is a small, early-phase trial, so results may not apply to all infants. The drug may not work as hoped in some babies, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates